Financial Data and Key Metrics Changes - The net investment income per share for Q3 2025 was $0.40, with a net asset value (NAV) per share of $12.75, reflecting a decrease of 2.1% from the previous quarter's NAV, partially due to a $0.16 per share special dividend and markdowns on underperforming assets [7][8] - The adjusted NAV per share for Q3 2025, accounting for the supplemental dividend, was $12.71, a non-GAAP measure introduced due to changes in the dividend policy [7] - The company declared a fourth quarter base dividend of $0.32 per share, with a net debt-to-equity ratio of 1.17 as of September 30, 2025, compared to 1.12 as of June 30, 2025 [8][15] Business Line Data and Key Metrics Changes - New investment commitments during the quarter totaled approximately $470.6 million across 27 portfolio companies, marking the highest level of new commitments since Q4 2021 [9] - 100% of originations in the quarter were in first-lien loans, indicating a continued focus on maintaining exposure to the top of the capital structure [9] - Total investments at fair value were $3.2 billion, with 98.2% in senior secured loans and a weighted average yield of 10.3% at amortized cost, down from 10.7% in the previous quarter [12][13] Market Data and Key Metrics Changes - The M&A market showed resilience, with total dollar volumes in Q3 2025 being 40.9% higher year-over-year compared to Q3 2024, driven by renewed risk-on sentiment among investors and lower borrowing costs [3][4] - The company noted that broader credit dynamics remain a concern, but it is comfortable with risk dynamics in the private credit space due to the overall health of portfolio fundamentals [5] Company Strategy and Development Direction - The company has adjusted its dividend policy to position itself well in a lower yield environment, emphasizing credit selection as a key focus [4] - The integration of the platform in 2022 has allowed the company to evaluate and invest in high-quality opportunities across various market segments [11] - The company aims to leverage its proximity to the investment banking franchise as a competitive advantage in evaluating opportunities [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the M&A activity being the start of a longer-term trend, driven by the need for private equity firms to exit existing portfolios and invest in new ones [22][23] - The company remains focused on maintaining its dividend and believes that fund managers will be rewarded for their credit selection in a lower-yielding environment [18] Other Important Information - The company repurchased over 2.1 million shares for $25.1 million during the quarter, which was NAV accretive [13] - The company issued $400 million of a five-year investment grade unsecured note with a coupon of 5.65%, which was oversubscribed [16] Q&A Session Summary Question: Thoughts on sustaining M&A activity into next year - Management believes the current M&A activity is the start of a longer-term trend, driven by the need for private equity firms to exit existing portfolios and invest in new ones [22][23] Question: Impact of increased activity on spreads - Management does not anticipate spreads to widen significantly in the near term, despite the increase in M&A activity [24] Question: Performance of non-accrual investment at Dental Brands - Management indicated that the non-accrual status was due to continued underperformance, but it represents a small exposure in the overall portfolio [25][26]

Core Insights - AcariaHealth is showcasing its innovative approach to specialty pharmacy solutions at the 2025 Healthcare Advocate Summit with a unique "Reimagine Access" Hackathon and expert sessions [1][6]. Group 1: Event Highlights - The "Reimagine Access" Hackathon will take place on September 2, 2025, focusing on real-world access challenges in healthcare, encouraging participants to brainstorm actionable solutions [2]. - An expert panel on biosimilars and market disruption is scheduled for September 4, 2025, where AcariaHealth leaders will discuss trends and payer mandates, along with a video highlighting the role of Provider Experience Managers [3]. - A roundtable discussion on the Medicare Prescription Payment Plan (M3P) will conclude the summit on September 5, 2025, providing an interactive platform for attendees to ask questions [5]. Group 2: Company Commitment - AcariaHealth emphasizes the importance of seamless access to care, aiming to reshape specialty pharmacy through innovation, advocacy, and compassion [6]. - The company is dedicated to supporting patients with complex conditions by leveraging its expertise and the resources of Centene Corporation, the largest Medicaid managed care organization [8].

Core Insights - Better Choice Company, Inc. has announced a definitive agreement with SRx Health Solutions, Inc. to convert $4 million in debt to equity, enhancing SRx Health's working capital and future cash flow [1] - This investment is contingent upon the merger between SRx Health and Better Choice, expected to close in late April, which will create a leading global health and wellness company [2] Company Overview - Better Choice Company, Inc. is focused on pet health and wellness, promoting nutrition-based products that cater to the growing trend of pet humanization and consumer health awareness [3] - The company primarily sells its products under the Halo brand, which emphasizes sustainably sourced ingredients and minimally processed options for pets [3] SRx Health Overview - SRx Health operates as a Canadian specialty pharmacy provider, focusing on comprehensive healthcare services from acute pharmaceutical needs to chronic disease management [4] - The company aims to expand its specialty pharmacy locations from 34 to 100 across Canada, with plans to extend its services internationally [4]

Core Insights - Better Choice Company is participating in the 2025 Bloom Burton & Co. Healthcare Investor Conference, highlighting its commitment to the pet health and wellness sector [1][2] - SRx Health, a Canadian healthcare service provider, will present at the same conference, showcasing its focus on specialty pharmacy services [1][5] Company Overview - Better Choice Company is dedicated to transforming the pet health industry by offering nutrition-based products aimed at enhancing the health and longevity of pets [3] - The company primarily markets its products under the Halo brand, which emphasizes sustainably sourced ingredients and minimally processed diets [3] SRx Health Overview - SRx Health specializes in the Specialty Pharmacy segment, providing comprehensive healthcare services that include patient support programs and clinical trials [5][6] - The company aims to expand its specialty pharmacy locations from 34 to 100 across Canada, focusing on chronic and rare diseases [6]